Compare Abeona Therapeutics Inc (ABEO) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Williams-Sonoma, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Williams-Sonoma, Inc. trades at $216.4 (market cap $26.36B). The key difference: Williams-Sonoma, Inc. is far larger — about 70.6× Abeona Therapeutics Inc's market cap, and Williams-Sonoma, Inc. pays a 1.36% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WSM | |
|---|---|---|
Market Cap | $373.32M | $26.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $240.06 |
52-Week Low | $4.17 | $163.62 |
Enterprise Value | $228.22M | $27.20B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Williams-Sonoma (WSM) trades at $222.49, down 2.22% today, with a bullish technical signal and strong profitability metrics including 54.01% ROE and 13.81% net margin. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2.03. Recent news highlights brand collaborations and dividend declarations, while cash flow trends show operational strength despite net outflows in 2025.
WSM presents a mixed outlook with robust fundamentals and analyst consensus leaning hold (60.72%), but risks include competitive pressures and macroeconomic sensitivity. The current price sits above the $215.50 consensus target, suggesting limited near-term upside despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
